Latest News and Press Releases

BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public...

BASEL, Switzerland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...

FDA Priority Review of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer on track for decision by December 20, 2020 target action dateNDA for relugolix...

BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...

Seven oral and poster presentations presented at the American Society for Reproductive Medicine (ASRM) 2020 Virtual CongressOral presentation on efficacy and safety data from Phase 3 SPIRIT program...

BASEL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan...

Relugolix had a similar rate of castration resistance-free survival in the subgroup of men with metastatic disease compared to leuprolide acetate (74% vs. 75%, respectively) and did not achieve...

Prostate cancer and uterine fibroids disproportionately impact Black Americans; racial disparities are exacerbated by inequities in healthcare access and COVID-19 pandemicMyovant expands ongoing...

Relugolix combination therapy maintained bone mineral density through one year, consistent with bone mineral density changes observed in untreated womenFindings presented at the American Society for...

FDA sets target action date of June 1, 2021 BASEL, Switzerland, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for...